Robert A. Wilcox

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes

Robert F. Storey, Steen Husted, Robert A. Harrington et al. · Journal of the American College of Cardiology · 2007 · 484 citations

Thrombopoiesis, Thrombosis, Platelet Aggregation Inhibitors +12

Textbook of Hypertension

Robert A. Wilcox · BMJ · 1995 · 336 citations

Blood Pressure Monitoring, Hypertension, Second Edition +11

Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

Erland Erdmann, B Charbonnel, Robert A. Wilcox et al. · Diabetes Care · 2007 · 280 citations · Full text

Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the “smoker's paradox” from the GUSTO-I trial, with angiographic insights

Gabriel I. Barbash, Jonathan Reiner, H. D. White et al. · Journal of the American College of Cardiology · 1995 · 247 citations

Tobacco Control, Thrombosis, Paradoxic Beneficial Effects +11

Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes

Keith G. Oldroyd, Robert A. Wilcox, Robert F. Storey · Thrombosis and Haemostasis · 2001 · 195 citations

Cardiovascular Pharmacology, Open Multicentre Study, Pharmacotherapy +21